Literature DB >> 10094875

Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen.

M J Mourits1, A G Van der Zee, P H Willemse, K A Ten Hoor, H Hollema, E G De Vries.   

Abstract

BACKGROUND: The increased risk of endometrial carcinoma following the use of tamoxifen has stimulated studies on endometrial diagnostic screening methods. In tamoxifen users the endometrial thickening observed with transvaginal ultrasonography (TVU) frequently cannot be confirmed by hysteroscopy or histology.
OBJECTIVE: The aim was to investigate the relationship between TVU and hysteroscopic and histologic endometrial findings in postmenopausal patients using tamoxifen.
METHODS: Fifty-three asymptomatic postmenopausal tamoxifen-using breast cancer patients underwent a gynecological examination combined with TVU. Patients with an endometrial thickness of >5 mm were offered hysteroscopy and endometrial biopsy.
FINDINGS: Thirty-one patients (58%) had an endometrial thickness of >5 mm with enhanced, inhomogeneous echogenicity. Hysteroscopy was performed in 22 patients and 3 underwent hysterectomy. Seven of 22 patients had endometrial polyps, histologically characterized by cystically dilated glands lined with atrophic epithelium and periglandular stromal condensation. Histology of the three hysterectomy specimens showed a similar picture of atrophic luminal epithelium, covering dilated glands lined with atrophic epithelium and surrounded by dense stroma, which resembled the histology of the endometrial polyps. In all three specimens the histologically measured endometrial thickness corresponded with that on TVU.
INTERPRETATION: Tamoxifen can induce specific endometrial changes consisting of cystically dilated glands with periglandular stromal condensation while the overlying epithelium remains atrophic. The changes occur either in the endometrium itself or as a protrusion of the endometrium, i.e., as endometrial polyps. These findings explain the discrepancy between ultrasound, hysteroscopy, and histology. Due to the high number of false-positive findings, TVU is not an effective screening instrument in these patients. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10094875     DOI: 10.1006/gyno.1998.5316

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

Review 1.  Challenges in the gynecologic care of premenopausal women with breast cancer.

Authors:  Jamie N Bakkum-Gamez; Shannon K Laughlin; Jani R Jensen; Clement O Akogyeram; Sandhya Pruthi
Journal:  Mayo Clin Proc       Date:  2011-02-09       Impact factor: 7.616

2.  The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium.

Authors:  M J E Mourits; K A Ten Hoor; A G J van der Zee; P H B Willemse; E G E de Vries; H Hollema
Journal:  J Clin Pathol       Date:  2002-07       Impact factor: 3.411

3.  The effect of adjuvant hormonal therapy on the endometrium and ovary of breast cancer patients.

Authors:  Ho Sung Kim; Yong Tark Jeon; Yong Beom Kim
Journal:  J Gynecol Oncol       Date:  2008-12-29       Impact factor: 4.401

Review 4.  Guidelines for monitoring patients taking tamoxifen treatment.

Authors:  P Neven; H Vernaeve
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.228

5.  The use of transvaginal sonography and vaginoscopic hysteroscopy in women on tamoxifen.

Authors:  M Paschopoulos; E Kontostolis; E D Lolis; G Koliopoulos; Y Alamanos; E Paraskevaidis
Journal:  JSLS       Date:  2001 Jul-Sep       Impact factor: 2.172

6.  Endometrial pathology in breast cancer patients: Effect of different treatments on ultrasonographic, hysteroscopic and histological findings.

Authors:  Maria LE Donne; Angela Alibrandi; Leonarda Ciancimino; Andrea Azzerboni; Benito Chiofalo; Onofrio Triolo
Journal:  Oncol Lett       Date:  2013-01-28       Impact factor: 2.967

Review 7.  The effect of tamoxifen on the genital tract.

Authors:  Sandra A Polin; Susan M Ascher
Journal:  Cancer Imaging       Date:  2008-06-30       Impact factor: 3.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.